Global HIV Vaccine Market Future Outlook

Description: Vaccine discovery, designing, research and development science is backed by several decades of knowledge. Every year, new vaccine for treating infectious diseases is entering in the market and their quality along with pharmacological efficacy is increasing. Innovative modalities have been found and market is overcrowded with the number of vaccines for different infectious diseases. In this scenario, absence of HIV vaccines becomes a pertinent question in front of investigators funded by both pharmaceutical companies and medical regulatory authorities. Gravity of the situation could also be understood by the fact that HIV clinical trials have failed to produce pharmacological benefits despite availability of suitable infrastructure. Simultaneously, HIV incidences are escalating tremendously across the globe due to which necessity for this vaccine is becoming more essential. All these facts support the imminent market introduction of HIV vaccines in global market to prevent progression and proliferation of AIDS epidemic.

Clinical trials are being done for across the globe for development of HIV vaccines and these efforts have yielded significant results. Investigators have identified artificial molecules that could mimic the HIV infection as result of which immune system would be activated. Their efficacy has been proved and clinical trials using them have yet to instigate. Several different modalities are also under investigation which may lead to development of relatively high cure rates. Certain receptors are also under investigation which has been found to be involved during initial phase of HIV infection. Immunoglobins may also serve as an ideal candidate due to their involvement in immune system activation. Beside this, several innovative modalities has been proposed for the treatment of HIV and emphasis is being given on the development of prophylactic vaccines. Several lead molecules have been discovered and their pharmacological efficacy is under investigation. In this way, investigators are expected to find some worthy candidate to the development of HIV vaccine.

Recombinant DNA technologies and genetic engineering has been widely used for the development of vaccines for several infectious diseases. These technologies are also being used for the development of HIV vaccines that would be commercialized in global market in coming years. Genetic manipulation of HIV is under consideration to develop a strain which have all molecular signatures but no pathogenicity. This decoy strain will activate the immune system to develop active immunity. Novel modalities include, use of recombinant molecules having higher immune eliciting capabilities. Computerized simulations are also being used for analysis of obscure vaccine candidates having pharmaceutical potential. This technology is expected to decrease the valuable time and precious resources utilized in the screening of proposed candidate. Furthermore, investigators are developing methodologies to find the effect of HIV gene expression on nonpathogenic bacterial/viral vectors.

Pharmaceutical companies have recognized the dearth of effective HIV medications due to which they are investing significant amount on research and development of HIV vaccines. Various candidates are at different stages of clinical trials and they would be introduced in market in coming years. Technology is developing at rapid rates due to which screening of selected candidate is expected to take place at lesser time. In this way, market winding times are expected to decrease due to lesser time in developmental phases. Manufacturing capabilities are highly developed but some tweaking has to be done according to HIV pathogen. Significant development in recombinant DNA technology and genetic engineering is also expected to accelerate the rate of HIV vaccine development. Investigators are also expected to find new modalities that will help in checking the AIDS. In this way, future of HIV vaccines market looks optimistic and it may be commercialized in next 5-10 years.

"Global HIV Vaccine Market Future Outlook" Report Highlights:

- Introduction to HIV Vaccines
- Issues Related to the Development of HIV Vaccines
- Parameters for Successful Commercialization of HIV Vaccines
- Global HIV Vaccines Market Opportunity Analysis
- Global HIV Vaccine Clinical Pipeline by Company & Phase
- Global HIV Vaccine Clinical Pipeline: 100 Vaccines
- Majority Vaccine in Preclinical Phase: 42 Vaccines
Contents:

1. Introduction to HIV Vaccines

2. Issues Related to the Development of HIV Vaccines
   2.1 Lack of Antigenicity
   2.2 HIV Polymorphism
   2.3 High Mutation Rates
   2.4 Compromised Immune System
   2.5 Integration with DNA

3. Parameters for Successful Commercialization of HIV Vaccines
   3.1 Long Term Efficacy
   3.2 Reduced Transmission
   3.3 Relapse Prevention
   3.4 Cost Effectiveness
   3.5 Manufacturing Scalability

4. Mechanism of HIV Vaccines

5. Global HIV Vaccines Market Opportunity Analysis
   5.1 Market Overview
   5.2 HIV Vaccine Clinical Pipeline Overview

6. Global HIV Incidence Rates

7. Global HIV Vaccine Market Dynamics
   7.1 Funding Scenario for HIV Vaccine
   7.2 Favorable Market Parameters
   7.3 HIV Vaccines Commercialization Challenges

8. Global HIV Vaccines Market Future Prospects

9. Global HIV Vaccine Clinical Pipeline by Company & Phase
   9.1 Research
   9.2 Preclinical
   9.3 Clinical
   9.4 Phase-I
   9.5 Phase-I/II
   9.6 Phase-II
   9.7 Phase-III
   9.8 Preregistration

10. Discontinued & Suspended HIV Vaccines in Clinical Pipeline by Company & Phase
    10.1 Discontinued
    10.2 Suspended
    10.3 No Development Reported

11. Competitive Landscape
    11.1 AlphaVax
    11.2 Antigen Express
    11.3 Argo Therapeutics
    11.4 Bionor Pharmaceuticals
    11.5 Celldex Therapeutics
    11.6 FIT Biotech
    11.7 Crucell Pharmaceutical
    11.8 GeneCure
    11.9 Genetic Immunity
    11.10 GenVec
    11.11 GeoVax Labs
    11.12 Glaxo Smithkline
    11.13 Immune Response BioPharma
    11.14 Inovio Pharmaceuticals
    11.15 Novartis
    11.16 Oncoly Biopharma
List of Figures:
Figure 1-1: Effects of HIV Disease
Figure 1-2: Methods of HIV Transmission
Figure 1-3: Modalities to Treat HIV Infection
Figure 2-1: Issues Related to the Development of HIV Vaccines
Figure 3-1: Requirements for Successful Commercialization of HIV Vaccines
Figure 4-1: Types of HIV Vaccines
Figure 4-2: Techniques to Develop HIV Vaccines
Figure 4-3: Mechanism of SAV001 Vaccine
Figure 4-4: Mechanism of AIDSVAX HIV Vaccine
Figure 4-5: Mechanism of V520 HIV Vaccine
Figure 5-1: HIV Vaccine Clinical Pipeline by Phase (%), 2015
Figure 5-2: HIV Vaccine Clinical Pipeline by Phase (Number), 2015
Figure 5-3: No Development Reported HIV Vaccine Clinical Pipeline by Phase (%), 2015
Figure 5-4: No Development Reported HIV Vaccine Clinical Pipeline by Phase (Number), 2015
Figure 5-5: Discontinued HIV Vaccine Clinical Pipeline by Phase (%), 2015
Figure 5-6: Discontinued HIV Vaccine Clinical Pipeline by Phase (Number), 2015
Figure 6-1: People Living With HIV Infection (Million), 2009-2014
Figure 6-2: New Incidence of HIV Infection (Million), 2009-2012
Figure 7-1: Global HIV Vaccines R&D Funding (US$ Million), 2005-2012
Figure 7-2: Global HIV Vaccines R&D Funding Breakup (%), 2012
Figure 7-3: Philanthropic Sector Spending on HIV Vaccines by Clinical Research Phase (%), 2012
Figure 7-4: HIV Vaccine Market Favorable Parameters
Figure 7-5: HIV Vaccines Commercialization Challenges
Figure 8-1: Estimated HIV Market Size with Routine Vaccination Only
Figure 11-1: AlphaVax Clinical Pipeline
Figure 11-2: Bionor Pharma Clinical Pipeline
Figure 11-3: TVAX Biomedical Clinical Pipeline

List of Tables:
Table 4-1: HIV Vaccine Antigens under Investigation
Table 6-1: Comparative Analysis of HIV Associated Features across the Globe
Table 7-1: HIV Vaccines Funding by Sector (US$ Million), 2006-2012
Table 8-1: Global Impact of a Vaccine on AIDS Incidence and Mortality

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3222190/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Global HIV Vaccine Market Future Outlook</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/3222190/">http://www.researchandmarkets.com/reports/3222190/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SC6IJX45</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Single User</td>
<td></td>
</tr>
<tr>
<td>Hard Copy</td>
<td>USD 2400 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>CD-ROM</td>
<td>USD 2400 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Enterprisewide</td>
<td></td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td>__________________________</td>
<td>Last Name:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World